<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE trials [
<!ELEMENT trials (trial+)>

<!ELEMENT trial (main,contacts,countries,criteria,health_condition_code,health_condition_keyword,intervention_code,
          intervention_keyword,primary_outcome,secondary_outcome,secondary_sponsor,secondary_ids,source_support,ethics_reviews)>

<!ELEMENT main (trial_id,utrn?,reg_name,date_registration,primary_sponsor,public_title,acronym?,scientific_title,scientific_acronym?,
          date_enrolment,type_enrolment,target_size,recruitment_status,url?,study_type,study_design,phase,hc_freetext?,i_freetext?,results_actual_enrolment,results_date_completed,results_url_link,results_summary,           results_date_posted,results_date_first_publication,results_baseline_char,results_participant_flow,results_adverse_events,results_outcome_measures,results_url_protocol,results_IPD_plan, results_IPD_description)>
<!ELEMENT trial_id (#PCDATA)>
<!ELEMENT utrn (#PCDATA)>
<!ELEMENT reg_name (#PCDATA)>
<!ELEMENT date_registration (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT primary_sponsor (#PCDATA)>
<!ELEMENT public_title (#PCDATA)>
<!ELEMENT acronym (#PCDATA)>
<!ELEMENT scientific_title (#PCDATA)>
<!ELEMENT scientific_acronym (#PCDATA)>
<!ELEMENT date_enrolment (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT type_enrolment (#PCDATA)>
<!ELEMENT target_size (#PCDATA)>
<!ELEMENT recruitment_status (#PCDATA)><!-- Pending,Recruiting,Suspended,Complete,Other -->
<!ELEMENT url (#PCDATA)>
<!ELEMENT study_type (#PCDATA)><!-- interventional,observational -->
<!ELEMENT study_design (#PCDATA)>
<!ELEMENT phase (#PCDATA)>
<!ELEMENT hc_freetext (#PCDATA)>
<!ELEMENT i_freetext (#PCDATA)>
<!ELEMENT results_actual_enrolment (#PCDATA)>
<!ELEMENT results_date_completed (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_url_link (#PCDATA)>
<!ELEMENT results_summary (#PCDATA)>
<!ELEMENT results_date_posted (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_date_first_publication (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT results_baseline_char (#PCDATA)>
<!ELEMENT results_participant_flow (#PCDATA)>
<!ELEMENT results_adverse_events (#PCDATA)>
<!ELEMENT results_outcome_measures (#PCDATA)>
<!ELEMENT results_url_protocol (#PCDATA)>
<!ELEMENT results_IPD_plan (#PCDATA)>
<!ELEMENT results_IPD_description (#PCDATA)>


<!ELEMENT contacts (contact+)>
<!ELEMENT contact (type,firstname,middlename,lastname,address,city,country1,zip,telephone,email,affiliation)>
<!ELEMENT type (#PCDATA)><!-- Public,Scientific -->
<!ELEMENT firstname (#PCDATA)>
<!ELEMENT middlename (#PCDATA)>
<!ELEMENT lastname (#PCDATA)>
<!ELEMENT address (#PCDATA)>
<!ELEMENT city (#PCDATA)>
<!ELEMENT country1 (#PCDATA)>
<!ELEMENT zip (#PCDATA)>
<!ELEMENT telephone (#PCDATA)>
<!ELEMENT email (#PCDATA)>
<!ELEMENT affiliation (#PCDATA)>

<!ELEMENT countries (country2+)>
<!ELEMENT country2 (#PCDATA)>

<!ELEMENT criteria (inclusion_criteria,agemin,agemax,gender,exclusion_criteria)>
<!ELEMENT inclusion_criteria (#PCDATA)>
<!ELEMENT agemin (#PCDATA)>
<!ELEMENT agemax (#PCDATA)>
<!ELEMENT gender (#PCDATA)>
<!ELEMENT exclusion_criteria (#PCDATA)>

<!ELEMENT health_condition_code (hc_code+)>
<!ELEMENT hc_code (#PCDATA)>

<!ELEMENT health_condition_keyword (hc_keyword+)>
<!ELEMENT hc_keyword (#PCDATA)>

<!ELEMENT intervention_code (i_code+)>
<!ELEMENT i_code (#PCDATA)>

<!ELEMENT intervention_keyword (i_keyword+)>
<!ELEMENT i_keyword (#PCDATA)>

<!ELEMENT primary_outcome (prim_outcome+)>
<!ELEMENT prim_outcome (#PCDATA)>

<!ELEMENT secondary_outcome (sec_outcome+)>
<!ELEMENT sec_outcome (#PCDATA)>

<!ELEMENT secondary_sponsor (sponsor_name+)>
<!ELEMENT sponsor_name (#PCDATA)>

<!ELEMENT secondary_ids (secondary_id+)>
<!ELEMENT secondary_id (sec_id,issuing_authority)>
<!ELEMENT sec_id (#PCDATA)>
<!ELEMENT issuing_authority (#PCDATA)>

<!ELEMENT source_support (source_name+)>
<!ELEMENT source_name (#PCDATA)>

<!ELEMENT ethics_reviews (ethics_review+)>
<!ELEMENT ethics_review (status,approval_date,contact_name,contact_address,contact_phone,contact_email)>
<!ELEMENT status (#PCDATA)><!-- Not approved,Approved,NA -->
<!ELEMENT approval_date (#PCDATA)><!-- dd/mm/yyyy -->
<!ELEMENT contact_name (#PCDATA)>
<!ELEMENT contact_address (#PCDATA)>
<!ELEMENT contact_phone (#PCDATA)>
<!ELEMENT contact_email (#PCDATA)>
]>
<trials>
  <trial>
    <main>
      <trial_id>IRCT20100314003566N9</trial_id>
      <utrn></utrn>
      <reg_name>IRCT</reg_name>
      <date_registration>2018-03-04</date_registration>
      <primary_sponsor>Vice chancellor for Research,Tabriz University Of Medical Sciences</primary_sponsor>
      <public_title>Comparative efficacy of intralesional Cryotherapy vs intralesional Corticosteroi   5 Fluorouracil   in the treatment of hypertrophic scars and keloids</public_title>
      <acronym></acronym>
      <scientific_title>Comparative efficacy of intralesional Cryotherapy vs intralesional Corticosteroid  5 Fluorouracil   in the treatment of hypertrophic scars and keloids</scientific_title>
      <scientific_acronym></scientific_acronym>
      <date_enrolment>2018-01-30</date_enrolment>
      <type_enrolment>anticipated</type_enrolment>
      <target_size>63</target_size>
      <recruitment_status>Complete</recruitment_status>
      <url>https://irct.ir/trial/29236</url>
      <study_type>interventional</study_type>
      <study_design>Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: This research is double-blinded experimental, interventional (clinical trial) study, in which researcher and patient are not aware of the treatment method, and patients would be distinguished with manual coding.
The patients are then randomly assigned to three distinct groups randomly by a random number table, Blinding description: This research is double-blinded experimental, interventional (clinical trial) study, in which researcher and patient are not aware of the treatment method, and patients would be distinguished with manual coding.The checklist will be prepared by the executor and will be completed individually for each patient, and then the patients will be randomly assigned to three distinct groups randomly by random number table, and each step will be evaluated by assistant.
Each method is performed by needle insertion after anesthesia which patient will be not aware of the material. 
The research is performed by executor and treatment response is analyzed by assistant.</study_design>
      <phase>2-3</phase>
      <hc_freetext>Other disorders of skin and subcutaneous tissue in diseases classified elsewhere.</hc_freetext>
      <i_freetext>Intervention 1: Intervention group: The first group will be treated with Intra lesional cryotherapy(sarmadarman co./iran) alone.In this method, a liquid nitrogen at a temperature of -196 c through a probe leads to freezing of the lesion.Treatment every 4 weeks, depending on the scar tissue, will be repeated up to 6 sessions. Intervention 2: Intervention group 2: Triamcinolone 40 mg / ml will be injected by 27 gauge needle into the lesion in the amount of 0.2 ml / cm² (steroid used in this study is triamhexal.)Treatment every 4 weeks, depending on the scar tissue, will be repeated up to 6 sessions. Intervention 3: Intervention group3: 5Fluorouracil(EBEWE.CO) 250 mg / 5mg  (0.2 ml / cm²) will be injected into the lesion by 27gauge needle.Treatment every 4 weeks, depending on the scar tissue, will be repeated up to 6 sessions.</i_freetext>
      <results_actual_enrolment></results_actual_enrolment>
      <results_date_completed></results_date_completed>
      <results_url_link></results_url_link>
      <results_summary></results_summary>
      <results_date_posted></results_date_posted>
      <results_date_first_publication></results_date_first_publication>
      <results_baseline_char></results_baseline_char>
      <results_participant_flow></results_participant_flow>
      <results_adverse_events></results_adverse_events>
      <results_outcome_measures></results_outcome_measures>
      <results_url_protocol></results_url_protocol>
      <results_IPD_plan>Undecided - It is not yet known if there will be a plan to make this available</results_IPD_plan>
      <results_IPD_description>Justification or reason for indecision in sharing IPD is After the completion of the project, the decision will be made.</results_IPD_description>
    </main>
    <contacts>
      <contact>
        <type>public</type>
        <firstname>Hamide Azimi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dermatology ward, Sina Hospital, Azadi Ave.</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>51386631357</zip>
        <telephone>+98 41 3553 9161</telephone>
        <email>azimi@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
      <contact>
        <type>scientific</type>
        <firstname>Hamide Azimi</firstname>
        <middlename></middlename>
        <lastname></lastname>
        <address>Dermatology ward, Sina Hospital, Azadi Ave. خیابان آزادی، بیمارستان سینا، بخش پوست</address>
        <city>Tabriz</city>
        <country1>Iran (Islamic Republic of)</country1>
        <zip>51386631357</zip>
        <telephone>+98 41 3553 9161</telephone>
        <email>azimi@tbzmed.ac.ir</email>
        <affiliation>Tabriz University of Medical Sciences</affiliation>
      </contact>
    </contacts>
    <countries>
      <country2>Iran (Islamic Republic of)</country2>
    </countries>
    <criteria>
      <inclusion_criteria>Patients withof hypertrophic scars and keloids
Age 12 and older</inclusion_criteria>
      <agemin>12 years</agemin>
      <agemax>no limit</agemax>
      <gender>Both</gender>
      <exclusion_criteria>Pregnant
Breastfeeding women
Age less than 12 years
history of allergy to the drugs used in the research
liver and kidney disease
Immune system deficiency
Reduction in blood cell levels</exclusion_criteria>
    </criteria>
    <health_condition_code>
      <hc_code>L99</hc_code>
    </health_condition_code>
    <health_condition_keyword>
      <hc_keyword>Other disorders of skin and subcutaneous tissue in diseases classified elsewhere</hc_keyword>
    </health_condition_keyword>
    <intervention_code>
      <i_code>Treatment - Other</i_code>
      <i_code>Treatment - Drugs</i_code>
      <i_code>Treatment - Drugs</i_code>
    </intervention_code>
    <intervention_keyword>
      <i_keyword>Intervention group: The first group will be treated with Intra lesional cryotherapy(sarmadarman co./iran) alone.In this method, a liquid nitrogen at a temperature of -196 c through a probe leads to freezing of the lesion.Treatment every 4 weeks, depending on the scar tissue, will be repeated up to 6 sessions.</i_keyword>
      <i_keyword>Intervention group 2: Triamcinolone 40 mg / ml will be injected by 27 gauge needle into the lesion in the amount of 0.2 ml / cm² (steroid used in this study is triamhexal.)Treatment every 4 weeks, depending on the scar tissue, will be repeated up to 6 sessions.</i_keyword>
      <i_keyword>Intervention group3: 5Fluorouracil(EBEWE.CO) 250 mg / 5mg  (0.2 ml / cm²) will be injected into the lesion by 27gauge needle.Treatment every 4 weeks, depending on the scar tissue, will be repeated up to 6 sessions.</i_keyword>
    </intervention_keyword>
    <primary_outcome>
      <prim_outcome>Scar Volume. Timepoint: Every 4 weeks, depending on the scar tissue, up to 6 sessions. Method of measurement: Using the vernier scale tool.</prim_outcome>
    </primary_outcome>
    <secondary_outcome>
      <sec_outcome>Complications of treatment. Timepoint: Monthly, up to 6 months. Method of measurement: Clinical observation.</sec_outcome>
    </secondary_outcome>
    <secondary_sponsor>
      <sponsor_name></sponsor_name>
    </secondary_sponsor>
    <secondary_ids>
      <secondary_id>
        <sec_id></sec_id>
        <issuing_authority></issuing_authority>
      </secondary_id>
    </secondary_ids>
    <source_support>
      <source_name>Vice chancellor for Research,Tabriz University Of Medical Sciences</source_name>
    </source_support>
    <ethics_reviews>
      <ethics_review>
        <status>Approved</status>
        <approval_date>2017-06-08</approval_date>
        <contact_name>Ethics Committee Of Tabriz University Of Medical Sciences.</contact_name>
        <contact_address>Third Floor, Central Building of Number2, Golgasht Street Tabriz East Azarbaijan Iran (Islamic Republic of)</contact_address>
        <contact_phone></contact_phone>
        <contact_email></contact_email>
      </ethics_review>
    </ethics_reviews>
  </trial>
</trials>
